Polymorphisms in the thymidylate synthase gene predict response to 5-Fluorouracil therapy in colorectal cancer

Clinical Colorectal Cancer

Volumn 5, Issue 5, 2006, Pages 321-323

  Gibson, Tara Beers ^c   Becerra, Carlos ^c   Chu, Edward ^a,b  

^a Section of Hematology and Medical Oncology   (United States)

^b YALE CANCER CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; MESSENGER RNA; THYMIDYLATE SYNTHASE;

5' UNTRANSLATED REGION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CORRELATION ANALYSIS; ENHANCER REGION; GENE DELETION; GENE EXPRESSION; GENOTYPE; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TANDEM REPEAT;

EID: 33244467276     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1533-0028(11)70202-X     Document Type: Article

References (14)

1. Haller DG. Update on chemotherapy for advanced colorectal cancer. Oncology (Williston Park) 2001; 15(3 suppl 5):11-15.
2. Kumar SK, Goldberg RM. Adjuvant chemotherapy for colon cancer. Curr Oncol Rep 2001; 3:94-101.
3. Aschele C, Debernardis D, Casazza S, et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999; 17:1760-1770.
4. Yamada H. Ichikawa W, Uetake H, et al. Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites. Clin Colorectal Cancer 2001; 1:169-173; discussion 174.
5. Horie N, Aiba H, Oguro K, et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20:191-197.
6. Kawakami K, Salonga D, Omura K, et al. Effects of polymorphic randem repeat sequence on the in vitro translation of messenger RNA. Proc Am Assoc Cancer Res 1999; 40:436-437.
7. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1:65-70.
8. Marsh S, McKay JA, Cassidy J, et al. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001; 19:383-386.
9. Iacopetta B, Grieu F, Joseph D, et al. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001; 85:827-830.
10. Villafranca E, Okruzhnov Y, Dominguez MA, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001; 19:1779-1786.
11. Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63:2898-2904.
12. Uchida K, Hayashi K, Kawakami K, et al. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin Cancer Res 2004; 10:433-439.
13. Lenz H, Zhang W, Zahedy S, et al. A 6 base-pair deletion in the 3′ UTR of the thymidylate synthase gene predicts TS mRNA expression in colorectal cancer: a possible candidate gene for colorectal cancer risk. Proc Am Assoc Cancer Res 2002; 43:660 (Abstract #3274).
14. McLeod H, Sargent D, Marsh S, et al. Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5-FU)/CPT-11, 5-FU/ oxaliplatin, or CPT-11/oxaliplatin therapy for advanced CRC. Proc Am Soc Clin Oncol 2003; 22:53 (Abstract #1013).